Effectiveness of a Psychosocial Weight Management Program for Individuals with Schizophrenia

  • Noosha Niv
  • Amy N. Cohen
  • Alison Hamilton
  • Christopher Reist
  • Alexander S. Young
Article

Abstract

The objective of this study was to examine the effectiveness of a weight loss program for individuals with schizophrenia in usual care. The study included 146 adults with schizophrenia from two mental health clinics of the Department of Veterans Affairs. The 109 individuals who were overweight or obese were offered a 16-week, psychosocial, weight management program. Weight and Body Mass Index (BMI) were assessed at baseline, 1 year later, and at each treatment session. Only 51% of those who were overweight or obese chose to enroll in the weight management program. Participants attended an average of 6.7 treatment sessions, lost an average of 2.4 pounds, and had an average BMI decrease of 0.3. There was no significant change in weight or BMI compared to the control group. Intervention strategies that both improve utilization and yield greater weight loss need to be developed.

Notes

Conflicts of interest

None.

References

  1. 1.
    Homel, P., Casey, D., & Allison, D. B. (2002). Changes in body mass index for individuals with and without schizophrenia. Schizophrenia Research, 55, 277-84.PubMedCrossRefGoogle Scholar
  2. 2.
    Dickerson, F. B., Brown, C. H., Kreyenbuhl, J. A., et al. (2006). Obesity among individuals with serious mental illness. Acta Psychiatrica Scandinavica, 113, 306-313.PubMedCrossRefGoogle Scholar
  3. 3.
    Marder, S. R., Essock, S. M., Miller, A. L., et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161(8), 1334-1349.PubMedCrossRefGoogle Scholar
  4. 4.
    Sokal, J., Messias, E., Dickerson, F. B., et al. (2004). Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous and Mental Disease, 192, 421–427.PubMedCrossRefGoogle Scholar
  5. 5.
    Mukherjee, S., Decina, P., Bocola, V., et al. (1996). Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Reist, C., Mintz, J., Albers, L.J., et al. (2007). Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. Journal of Clinical Psychopharmacology, 27, 46–51.PubMedCrossRefGoogle Scholar
  7. 7.
    McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Canadian Journal of Psychiatry, 46(3), 273-81.Google Scholar
  8. 8.
    Davidson, M. H., Hauptman, J., DiGirolamo, et al. (1999). Weight control and risk factor reduction in obese subjects treated for two years with orlistat: a randomized controlled trial. Journal of the American Medical Association, 281, 235-242.PubMedCrossRefGoogle Scholar
  9. 9.
    Gordon, A. & Price, L. H. (1999). Mood stabilization and weight loss with topiramate. American Journal of Psychiatry, 156, 968-969.PubMedGoogle Scholar
  10. 10.
    Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000). Orlistat, a new lipase inhibitor for the management of obesity. Pharmocotherapy, 20, 270-279.CrossRefGoogle Scholar
  11. 11.
    McMahon, F. G., Fujioka, K., Singh, B. N., et al. (2000). Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine, 160, 2185-91.PubMedCrossRefGoogle Scholar
  12. 12.
    Sjostrom, L., Rissanen, A., Andersen, T., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167-172.PubMedCrossRefGoogle Scholar
  13. 13.
    Newcomer, J.W. (2007).Antipsychotic medications: metabolic and cardiovascular risk. Journal of Clinical Psychiatry, 68 Suppl 4, 8-13.PubMedGoogle Scholar
  14. 14.
    Newcomer, J.W., Campos, J.A., Marcus, R.N., et al. (2008). A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry, 69(7), 1046-1056.PubMedCrossRefGoogle Scholar
  15. 15.
    Brown, C., Goetz, J., Van Sciver, A., et al. (2006). A psychiatric rehabilitation approach to weight loss. Psychiatric Rehabilitation Journal, 29, 267-273.PubMedCrossRefGoogle Scholar
  16. 16.
    Faulkner, G., Cohn, T., & Remington, G. (2007). Interventions to reduce weight gain in schizophrenia. Schizophrenia Bulletin, 33(3), 654-656.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Littrell, K. H., Hilligoss, N. M., Kirshner, C. D., et al. (2003). The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship, 35(3), 237-241.PubMedCrossRefGoogle Scholar
  18. 18.
    Menza, M., Vreeland, B., Minsky, S., et al. (2004). Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry, 65(4), 471-477.PubMedCrossRefGoogle Scholar
  19. 19.
    Vreeland, B., Minsky, S., Menza, M., et al. (2003). A program for managing weight gain associated with atypical antipsychotics. Psychiatric Services, 54(8), 1155-1157.PubMedCrossRefGoogle Scholar
  20. 20.
    Alvarez-Jimenez, M., Hetrick, S. E., Gonzalez-Blanch, C., et al. (2008). Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry, 193(2), 101-107.PubMedCrossRefGoogle Scholar
  21. 21.
    Faulkner, G., & Cohn, T. A. (2006). Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Canadian Journal of Psychiatry, 51(8), 502-511.Google Scholar
  22. 22.
    Faulkner, G., Soundy, A. A., & Lloyd, K. (2003). Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatrica Scandinavica, 108(5), 324-332.PubMedCrossRefGoogle Scholar
  23. 23.
    Loh, C., Meyer, J. M., & Leckband, S. G. (2006). A comprehensive review of behavioral interventions for weight management in schizophrenia. Annals of Clinical Psychiatry, 18(1), 23-31.PubMedCrossRefGoogle Scholar
  24. 24.
    Brar, J. S., Ganguli, R., Pandina, G., et al. (2005). Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry, 66(2), 205-212.PubMedCrossRefGoogle Scholar
  25. 25.
    Brown, S. & Chan, K. (2006). A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. Journal of Mental Health, 15, 543-549.CrossRefGoogle Scholar
  26. 26.
    Jean-Baptiste, M., Tek, C., Liskov, E., et al. (2007). A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia Research, 96(1-3), 198-205.PubMedCrossRefGoogle Scholar
  27. 27.
    Kwon, J. S., Choi, J. S., Bahk, W. M., et al. (2006). Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry, 67(4), 547-553.PubMedCrossRefGoogle Scholar
  28. 28.
    McKibbin, C. L., Patterson, T. L., Norman, G., et al. (2006) A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophrenia Research, 86(1-3), 36-44.PubMedCrossRefGoogle Scholar
  29. 29.
    Melamed, Y., Stein-Reisner, O., Gelkopf, M., et al. (2008). Multi-modal weight control intervention for people with persistent mental disorders. Psychiatric Rehabilitation Journal, 31(3), 194-200.PubMedCrossRefGoogle Scholar
  30. 30.
    Weber, M., & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research, 83(1), 95-101.PubMedCrossRefGoogle Scholar
  31. 31.
    Wu, M. K., Wang, C. K., Bai, Y. M., et al. (2007). Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatric Services, 58(4), 544-550.PubMedCrossRefGoogle Scholar
  32. 32.
    Cutler, J. (1997). Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the trials of Hypertension Prevention, Phase II. Archives of Internal Medicine, 157, 657-667.CrossRefGoogle Scholar
  33. 33.
    Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403.PubMedCrossRefGoogle Scholar
  34. 34.
    Lean, M. E., Powrie, J. K., Anderson, A. S., et al. (1990). Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Medicine, 7(3), 228-233.PubMedCrossRefGoogle Scholar
  35. 35.
    National Institutes of Health. (1998). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Washington: National Institutes of Health: NIH Pub #98-4083.Google Scholar
  36. 36.
    Sonne-Holm, S., Sorensen, T., Jensen, G., et al. (1989). Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. British Medical Journal, 299, 767-770.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Tuomilehto, J., Lindstrom, J., Eriksson, J. G., et al. (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 344(18), 1343-1350.PubMedCrossRefGoogle Scholar
  38. 38.
    Brown, A.H., Cohen, A. N., Chinman, M. J., et al. (2008). EQUIP: Implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia. Implementation Science, 15, 3-9.Google Scholar
  39. 39.
    First, M., Spitzer, R., Gibbon, M., et al. (1995). Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (fourth ed, Patient Edition, version 2.0 ed.). New York, NY: New York State Psychiatric Institute.Google Scholar
  40. 40.
    Ryan, S., Littrell, K., Sowers, C., et al. (2000). Solutions for Wellness. Indianapolis, IN: Eli Lilly.Google Scholar
  41. 41.
    Schiefler, P. (2002). Partnership for Recovery: (Available from Center for Excellence in Psychiatry, University Behavioral Healthcare, 151 Centennial Avenue, Suite 1500, Piscataway, NJ, 08854).Google Scholar
  42. 42.
    Dixon, L. B., Dickerson, F., Bellack, A. S., et al. (2010). The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. Schizophrenia Bulletin, 36, 48-70.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Damschroder, L. J., Aron, D. C., Keith, R. E., et al. (2009). Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Science 4, 50.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Backer, T. E., Liberman, R. P., & Kuehnel, T. G. (1986). Dissemination and adoption of innovative psychosocial interventions. Journal of Consulting and Clinical Psychology, 54, 111–118.PubMedCrossRefGoogle Scholar
  45. 45.
    Archie, S., Wilson, J. H., Osborne, S., et al. (2003). Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. Canadian Journal of Psychiatry, 48, 628-632.Google Scholar
  46. 46.
    Beebe, L. H. & Smith, K. (2010). Feasibility of the Walk, Address, Learn and Cue (WALC) intervention for schizophrenia spectrum disorders. Archives of Psychiatric Nursing, 24, 54-62.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Beebe, L. H., Tian, L., Morris, N., et al. (2005). Effects of exercise on mental and physical health parameters of persons with schizophrenia. Issues in Mental Health Nursing, 26, 661-676.PubMedCrossRefGoogle Scholar

Copyright information

© National Council for Community Behavioral Healthcare (outside the U.S.) 2012

Authors and Affiliations

  • Noosha Niv
    • 1
    • 3
  • Amy N. Cohen
    • 1
  • Alison Hamilton
    • 1
  • Christopher Reist
    • 2
  • Alexander S. Young
    • 1
  1. 1.VA Desert Pacific MIRECC and University of California Los Angeles, Department of Psychiatry and Biobehavioral SciencesLos AngelesUSA
  2. 2.VA Desert Pacific MIRECC and University of Califonia IrvineDepartment of Psychiatry and Human BehaviorIrvineUSA
  3. 3.Long Beach VA, MIRECCLong BeachUSA

Personalised recommendations